Eight US manufacturers selected to make NASA COVID-19 ventilator

Eight US manufacturers selected to make NASA COVID-19 ventilator

Press releases may be edited for formatting or style | June 01, 2020
WASHINGTON, May 29, 2020 /PRNewswire/ -- After receiving more than 100 applications, NASA's Jet Propulsion Laboratory (JPL) in Southern California has selected eight U.S. manufacturers to make a new ventilator tailored for coronavirus (COVID-19) patients.

The prototype, which was created by JPL engineers in just 37 days, received an Emergency Use Authorization from the Food and Drug Administration on April 30.

Called VITAL (Ventilator Intervention Technology Accessible Locally), the high-pressure ventilator was designed to use one-seventh the parts of a traditional ventilator, relying on parts already available in supply chains. It offers a simpler, more affordable option for treating critical patients while freeing up traditional ventilators for those with the most severe COVID-19 symptoms. Its flexible design means it also can be modified for use in field hospitals.

THE (LEADER) IN MEDICAL IMAGING TECHNOLOGY SINCE 1982. SALES-SERVICE-REPAIR

Special-Pricing Available on Medical Displays, Patient Monitors, Recorders, Printers, Media, Ultrasound Machines, and Cameras.This includes Top Brands such as SONY, BARCO, NDS, NEC, LG, EDAN, EIZO, ELO, FSN, PANASONIC, MITSUBISHI, OLYMPUS, & WIDE.

The Office of Technology Transfer and Corporate Partnerships at Caltech, which owns the patents and software for VITAL, is offering a free license for the device. Caltech manages JPL for NASA.

The U.S. companies selected for licenses are:

Vacumed, a division of Vacumetrics, Inc. in Ventura, California
Stark Industries, LLC in Columbus, Ohio
MVent, LLC, a division of Minnetronix Medical, in St. Paul, Minnesota
iButtonLink, LLC in Whitewater, Wisconsin
Evo Design, LLC in Watertown, Connecticut
DesignPlex Biomedical, LLC in Fort Worth, Texas
ATRON Group, LLC in Dallas
Pro-Dex, Inc. in Irvine, California
"The VITAL team is very excited to see their technology licensed," said Leon Alkalai, manager of the JPL Office of Strategic Partnerships and a member of the VITAL leadership team. "Our hope is to have this technology reach across the world and provide an additional source of solutions to deal with the on-going COVID-19 crisis."

JPL now is evaluating international manufacturers from countries as diverse as Brazil, Mexico, India and Malaysia. A full list of approved manufacturers is available here.

VITAL was developed with input from doctors and medical device manufacturers. A prototype of the JPL device was successfully tested by the Human Simulation Lab in the Department of Anesthesiology, Perioperative and Pain Medicine at Mount Sinai on April 23.

A modified design, which uses compressed air and can be deployed by a greater range of hospitals, was recently tested at the UCLA Simulation Center in Los Angeles. A high-fidelity lung simulator tested almost 20 different ventilator settings, representing a number of scenarios that could be seen in critically ill patients in an intensive care unit.

"VITAL performed well in simulation testing with both precise and reproducible results," said Dr. Tisha Wang, clinical chief of the UCLA Division of Pulmonary and Critical Care Medicine. "In addition, the setup and operation of the ventilator was quick and user-friendly. The UCLA team commends JPL for actively contributing to the COVID-19 response and successfully addressing one of the key medical needs in the sickest group of patients."

The compressed-air design also has been submitted to the FDA for a ventilator Emergency Use Authorization and is currently under review.

You Must Be Logged In To Post A Comment